Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy.
AI screening identified a drug candidate that shuts down the toxic DUX4 protein in muscle cells, offering hope for FSHD—a rare dystrophy with no approved treatment.
An AI-based virtual screening pipeline identified C06 as a potent DUX4 repressor in FSHD myocytes through BAZ1A bromodomain targeting, also acting via p38α inhibition, with a favorable transcriptome profile at low doses. This provides a novel therapeutic candidate for FSHD — a rare muscular dystrophy with no approved disease-modifying therapy.
What the study was
- Study design
- AI-based drug screening + functional validation in FSHD myocytes (in vitro)
- Population
- FSHD patient-derived myocytes (in vitro), with BAZ1A bromodomain as target
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Scientific Reports
Why it surfaced
FSHD has high unmet need (no approved treatment); AI drug discovery with BAZ1A bromodomain target is novel. In vitro only — caps score at 5 per rules for non-human studies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.